Drug Interaction Report
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- deferiprone
- treosulfan
Drug interactions
Major drug interactions
Major:treosulfan deferiprone
Applies to: treosulfan, deferiprone
Deferiprone can lower white blood cell count, and combining it with other medications like treosulfan that can also affect white blood cells or bone marrow function may increase the risk. You may be more likely to develop serious and potentially life-threatening infections as a result.
You should seek immediate medical attention if you have signs and symptoms of infection such as:
- fever
- chills
- diarrhea
- sore throat
- muscle aches
- shortness of breath
- blood in phlegm
- weight loss
- red or inflamed skin
- body sores
- pain or burning during urination
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need more frequent monitoring to safely use both medications.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Disease interactions
6 potential interactionsApplies to: 5 conditions, including Seizures, Liver Disease, Infection, Neutropenia, and Renal Dysfunction.
Infection
Major:deferiprone
Deferiprone has a major potential interaction with Infection.
Fatal agranulocytosis and neutropenia can occur with the use of deferiprone. It is recommended to obtain an absolute neutrophil count before initiating treatment with deferiprone and monitor weekly thereafter or as clinically appropriate. Manage agranulocytosis/neutropenia prior to initiating treatment. Therapy should be interrupted if neutropenia develops or if an infection develops. Do not resume therapy in patients who have developed agranulocytosis and do not rechallenge patients who develop neutropenia unless potential benefits outweigh potential risks.
Liver Disease
Moderate:deferiprone
Deferiprone has a moderate potential interaction with Liver Disease.
A clinical study to evaluate the effect of impaired hepatic function on the pharmacokinetics of deferiprone showed that mild and moderate hepatic impairment do not influence the pharmacokinetics of deferiprone and major metabolite, deferiprone 3-O-glucuronide. Based on the results, no dose adjustment is required in patients with mildly or moderately hepatic impairment. Caution is recommended when using this agent in patients with severe hepatic impairment as the pharmacokinetics of deferiprone and deferiprone have not been evaluated. It is recommended to monitor serum transaminase values monthly during therapy and to consider interruption if there is a persistent increase in serum transaminase levels. Close monitoring is recommended.
Moderate:treosulfan
Treosulfan has a moderate potential interaction with Liver Disease.
Treosulfan has not been studied in patients with moderate or severe liver and renal dysfunction.
Neutropenia
Major:deferiprone
Deferiprone has a major potential interaction with Neutropenia.
Fatal agranulocytosis and neutropenia can occur with the use of deferiprone. It is recommended to obtain an absolute neutrophil count before initiating treatment with deferiprone and monitor weekly thereafter or as clinically appropriate. Manage agranulocytosis/neutropenia prior to initiating treatment. Therapy should be interrupted if neutropenia develops or if an infection develops. Do not resume therapy in patients who have developed agranulocytosis and do not rechallenge patients who develop neutropenia unless potential benefits outweigh potential risks.
Renal Dysfunction
Moderate:treosulfan
Treosulfan has a moderate potential interaction with Renal Dysfunction.
Treosulfan has not been studied in patients with moderate or severe liver and renal dysfunction.
Seizures
Moderate:treosulfan
Treosulfan has a moderate potential interaction with Seizures.
There have been reports of seizures in patients following treatment with treosulfan. Patients should be monitored for signs of neurological adverse reactions, and clonazepam prophylaxis may be considered for patients at higher risk for seizures, including infants.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.